BioCryst Pharmaceuticals Inc
$ 7.90
4.64%
26 Feb - close price
- Market Cap 1,872,695,000 USD
- Current Price $ 7.90
- High / Low $ 8.20 / 7.59
- Stock P/E N/A
- Book Value -1.84
- EPS -0.05
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE -19.25 %
- 52 Week High 11.31
- 52 Week Low 6.00
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
Analyst Target Price
$21.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-03 | 2025-08-05 | 2025-05-05 | 2025-02-24 | 2024-11-04 | 2024-08-05 | 2024-05-06 | 2024-02-26 | 2023-11-02 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 0 | 0.16 | 0.02 | 0.0001 | -0.13 | -0.07 | -0.06 | -0.17 | -0.28 | -0.19 | -0.24 | -0.28 |
| Estimated EPS | 0.0344 | 0.05 | 0.01 | -0.21 | -0.0604 | -0.06 | -0.17 | -0.21 | -0.24 | -0.23 | -0.23 | -0.3 |
| Surprise | -0.0344 | 0.11 | 0.01 | 0.2101 | -0.0696 | -0.01 | 0.11 | 0.04 | -0.04 | 0.04 | -0.01 | 0.02 |
| Surprise Percentage | -100% | 220% | 100% | 100.0476% | -115.2318% | -16.6667% | 64.7059% | 19.0476% | -16.6667% | 17.3913% | -4.3478% | 6.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCRX
2026-02-25 09:51:57
Coherent Market Insights has released a new report on the Hereditary Angioedema (HAE) market, forecasting its growth from 2026 to 2033. The report analyzes market trends, competition, geographic distribution, and growth potential, providing insights for entrepreneurs and investors. Key players such as BioCryst Pharmaceuticals and Pharming Group are highlighted, along with market segmentation by type, population, and setting.
2026-02-23 16:42:00
Evercore ISI has reinstated coverage of BioCryst Pharmaceuticals (BCRX) with an Outperform rating and a $17 price target, citing strong long-term growth potential. This outlook is attributed to the recent acquisition of Astria Therapeutics, expectations for Orladeyo to reach $900 million in peak sales by 2029, and Navenibart's potential for $1 billion in risk-adjusted revenue. BioCryst also announced it will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 AAAAI Annual Meeting, including new data on ORLADEYO and navenibart.
2026-02-23 14:43:39
BioCryst Pharmaceuticals (BCRX) has recently seen its share price rebound by about 10% over the last week and month, despite a 10% decline over the past year. The company's most popular narrative suggests a fair value of $20.50 per share against its current price of $7.45, implying it is significantly undervalued. This valuation hinges on strong and sustainable revenue growth for its drug ORLADEYO and transitioning from current losses to profitability.
2026-02-19 16:28:23
BioCryst Pharmaceuticals (BCRX) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended December 2025. The company has a Zacks Earnings ESP of +23.08% and a Zacks Rank #3 (Hold), suggesting a high probability of beating consensus EPS estimates. Investors should also consider other factors beyond the earnings beat or miss.
2026-02-18 17:57:30
Evercore ISI has resumed coverage of BioCryst Pharma with an outperform rating and a $17.00 price target following the acquisition of ATXS. The firm sees 150% upside from current levels, aligning with a "Strong Buy" consensus, though acknowledging near-term uncertainty due to upcoming prophylaxis data. BioCryst recently reported strong full-year 2025 revenue from its ORLADEYO treatment and impressive Q4 sales.
2026-02-18 15:52:50
Evercore ISI has resumed coverage of BioCryst Pharma (NASDAQ:BCRX) with an "outperform" rating and a price target of $17.00, representing a 150% upside. This decision follows BioCryst's acquisition of ATXS and aligns with a "Strong Buy" consensus from other analysts. While near-term returns are uncertain due to upcoming prophylaxis data in Q3 2026, the firm is evaluating the stock over a one-to-two-year timeframe and has added it to its Core SMID list.
